Literature DB >> 1320693

Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells.

K S Lee1.   

Abstract

Ibutilide, a class III antiarrhythmic compound under clinical development, was tested for specific activity on inward currents in guinea pig ventricular cells. Current clamp experiments showed a bell-shaped, dose-dependent effect of the compound on action potential duration and plateau height at concentrations beginning at 10(-9) M. In voltage clamp experiments in which the cells were bathed in K(+)-free solutions that contained external Na+0 and Ca++0, ibutilide, at 10(-8) M, increased a late inward current without affecting the fast inward Na+ current. The late inward current amplitudes, measured at 60 and 600 msec into a +20-m V step from -80 mV, were increased, respectively, from 0.73 +/- 0.07 to 1.1 +/- 0.06 nA, and from 0.02 +/- 0.02 to 0.15 +/- 0.03 nA, with a corresponding Kd of 2.3 x 10(-9) and 1.3 x 10(-9) M. However, if Na+0 was removed via appropriate ion substitution, the effect of ibutilide on the late inward current disappeared. On the other hand, when inward currents were maximized by the drug in Na+0 and Ca++0 containing external solution, removal of Na+0 reversibly removed a prominent late inward current which, when isolated from the L-type Ca++ current by current subtraction method, displayed a peak current potential of +30 mV and two decaying time constants of 38.2 +/- 3.8 and 200.8 +/- 43.3 msec at +20 mV. We concluded that ibutilide prolonged action potential duration through activation of a slow inward Na+ current. The identity of this current was discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320693

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation.

Authors:  R H Foster; M I Wilde; A Markham
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Pharmacologic enhancement of atrial electrical defibrillation efficacy: role of ibutilide.

Authors:  D S Khoury; M D Assar; H Sun
Journal:  J Interv Card Electrophysiol       Date:  1997-12       Impact factor: 1.900

3.  Frequency-dependent electrophysiological effect of ibutilide on human atrium and ventricle.

Authors:  N Oshikawa; I Watanabe; R Masaki; A Shindo; T Kojima; S Saito; Y Ozawa; K Kanmatsuse
Journal:  J Interv Card Electrophysiol       Date:  2001-03       Impact factor: 1.900

Review 4.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

Review 5.  Pharmacogenetics of Potassium Channel Blockers.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2016-06

Review 6.  Novel delivery of antiarrhythmic agents.

Authors:  V Labhasetwar; R J Levy
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

7.  Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.

Authors:  James E Tisdale; Brian R Overholser; Heather A Wroblewski; Kevin M Sowinski; Kwadwo Amankwa; Steven Borzak; Joanna R Kingery; Rita Coram; Douglas P Zipes; David A Flockhart; Richard J Kovacs
Journal:  J Clin Pharmacol       Date:  2011-11-01       Impact factor: 3.126

8.  Effects of sodium channel blockade on ibutilide induced prolongation of repolarization in the isolated rabbit ventricle.

Authors:  M A Wood; I Fuller; A Hong
Journal:  J Interv Card Electrophysiol       Date:  2000-10       Impact factor: 1.900

9.  Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.

Authors:  M A Vos; S R Golitsyn; K Stangl; M Y Ruda; L V Van Wijk; J D Harry; K T Perry; P Touboul; G Steinbeck; H J Wellens
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

10.  Prevailing Effects of Ibutilide on Fast Delayed Rectifier K+ Channel.

Authors:  Sodikdjon A Kodirov; Vladimir L Zhuravlev; Johannes Brachmann
Journal:  J Membr Biol       Date:  2019-10-04       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.